Literature DB >> 2981673

Specific receptors for vasopressin in the pituitary gland: evidence for down-regulation and desensitization to adrenocorticotropin-releasing factors.

B Koch, B Lutz-Bucher.   

Abstract

Specificity of binding of 3H-labeled arginine vasopressin [( 3H]AVP), down-regulation of receptors, and desensitization were studied in anterior pituitary glands of both Wistar and Brattleboro rats. Studies using both crude membrane fractions and isolated cells of anterior pituitaries revealed the presence of a single population of binding sites with a Kd of approximately 1 nM. The receptor recognized the following peptides, with AVP = lysine vasopressin = vasotocin greater than oxytocin = 1-deamino-(8-D-AVP) greater than d-(CH2)5-Tyr-(Me)-Val4-AVP greater than 1-deaminopenicillamine-(Val4-D-Arg8)VP. Neither corticotropin-releasing factor (CRF) nor any of the neuropeptides tested, including AVP ring and tail fragments, competed for tracer binding. Increased extracellular vasopressin levels due to chronic injections or long term adrenalectomy decreased receptor density by 80%, while oxytocin was less effective than AVP. Comparing binding data in Brattleboro homozygotes and heterozygotes revealed that AVP levels within the physiological range could down-regulate pituitary receptors as well. This could not be caused by occupation of sites by endogeneous vasopressin, since injection of large doses of peptide decreased tracer binding by less than 10%. Loss of pituitary receptors reduced 1) enhancement by AVP of CRF-induced cAMP accumulation, 2) intrinsic CRF-like activity and 3) synergistic effect of AVP on ACTH secretion elicited by CRF. This study thus provides evidence for the presence of highly specific vasopressin receptors in the anterior pituitary, which may undergo homologous down-regulation and desensitization in terms of cAMP production and ACTH release.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981673     DOI: 10.1210/endo-116-2-671

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

1.  Vasopressin-induced turnover of phosphatidylinositol in the sensory nervous system of the rat.

Authors:  A M Horn; S L Lightman
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

2.  Dissociation between activation of the hypothalamo-hypophyseal antidiuretic system and the type of diuresis during acute intracranial hypertension. Experimental observation.

Authors:  Z M Rap; M Koca; G Hildebrandt; H W Mueller; H W Pia
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 3.  The role of intracellular messengers in adrenocorticotropin secretion in vitro.

Authors:  M S King; A J Baertschi
Journal:  Experientia       Date:  1990-01-15

4.  Effects of adrenalectomy and glucocorticoids on the peptides CRF-41, AVP and oxytocin in rat hypophysial portal blood.

Authors:  G Fink; I C Robinson; L A Tannahill
Journal:  J Physiol       Date:  1988-07       Impact factor: 5.182

5.  Bacterial lipopolysaccharide-induced coordinate downregulation of arginine vasopressin receptor V3 and corticotropin-releasing factor receptor 1 messenger ribonucleic acids in the anterior pituitary of endotoxemic steers.

Authors:  Isam M Qahwash; Carolyn A Cassar; Roy P Radcliff; George W Smith
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

6.  Evidence for arginine vasopressin as the primary activator of the HPA axis during adjuvant-induced arthritis.

Authors:  H S Chowdrey; P J Larsen; M S Harbuz; D S Jessop; G Aguilera; D J Eckland; S L Lightman
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

7.  Role of appendages in skin resistance and iontophoretic peptide flux: human versus snake skin.

Authors:  W H Craane-van Hinsberg; J C Verhoef; L J Bax; H E Junginger; H E Boddé
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

8.  Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH.

Authors:  R A Salata; D B Jarrett; J G Verbalis; A G Robinson
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.